ADDF Town Hall - July 2024

Dr. Howard Fillit, Co-Founder and Chief Science Officer, and Jane McIntosh, Chief Philanthropy and External Affairs Officer, discuss how the recent FDA advisory committee's endorsement of donanemab, milestones for ADDF-funded clinical trials and biomarker programs, and advances in precision prevention are bringing us closer than ever to the holy grail of combination therapies and precision medicine.